LINC00520 Regulates VDAC1 Oligomerization to Promote Cisplatin Resistance in Lung Adenocarcinoma
Frontiers in Bioscience-Landmark · 2026-10-10 · 31 (10)
DOI: 10.31083/fbl53197 ↗At a glance
Journal article in Frontiers in Bioscience-Landmark, published online on 2026-10-10. Written by Ziyao Wang and 10 co-authors. Institution: Department of Thoracic Surgery, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, 410013 …. Major MEDLINE topics: Voltage-Dependent Anion Channel 1, Cisplatin, Drug Resistance, Neoplasm, RNA, Long Noncoding. 43 references. The full text is freely available (open access, CC BY 4.0). Funded by: Over-seas Expertise Introduction Project for Discipline Innovation (111 Project), Hunan Provincial Natural Science Foundation, Hunan Provincial Health Commission.
Abstract (original language)
Background
Platinum-based chemotherapy remains the primary treatment for lung adenocarcinoma (LUAD), although its efficacy is frequently limited by acquired cisplatin resistance. The involvement of long non-coding RNAs (lncRNAs) in this resistance is not well understood.
Methods
Differentially expressed lncRNAs were identified through bioinformatics analysis. LINC00520 expression was further validated in LUAD clinical specimens and cisplatin (CDDP)-resistant A549 cells. MS2-tagged RNA affinity purification (MS2-TRAP) coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to screen for LINC00520-interacting proteins, which were subsequently validated by RNA immunoprecipitation (RIP). Functional assays, including Cell Counting Kit-8 (CCK-8), colony formation, and apoptosis analysis, were conducted. Voltage-dependent anion-selective channel protein 1 (VDAC1) oligomerization and mitochondrial apoptosis were assessed by western blotting and 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) staining. In vivo xenograft models were used to corroborate key findings.
Results
LINC00520 was markedly upregulated in LUAD tissues and A549/CDDP-resistant cells, and elevated expression correlated with poor prognosis. Functionally, LINC00520 promoted proliferation, suppressed apoptosis, and enhanced cisplatin resistance, whereas its knockdown restored chemosensitivity. Mechanistically, LINC00520 directly bound VDAC1 and inhibited its oligomerization, thereby suppressing mitochondrial apoptosis. In vivo, LINC00520 silencing suppressed tumor growth and partially restored cisplatin sensitivity.
Conclusions
LINC00520 drives cisplatin resistance in LUAD by modulating VDAC1-mediated mitochondrial apoptosis, suggesting that LINC00520 may represent a potential prognostic biomarker and therapeutic target for reversing cisplatin resistance in LUAD.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Thoracic Surgery, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, 410013 Changsha, Hunan, China.
- Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, 050011 Shijiazhuang, Hebei, China.
- NHC Key Laboratory of Carcinogenesis, Key Laboratory of Carcinogenesis, Chinese Ministry of Health, Xiangya School of Basic Medical Sciences, Central South University, 410013 Changsha, Hunan, China.
- Department of Diagnostic Radiology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, 410013 Changsha, Hunan, China.
- Departments of Respiratory and Critical Care Medicine, Peking University Shenzhen Hospital, 518036 Shenzhen, Guangdong, China.
Funding
- Over-seas Expertise Introduction Project for Discipline Innovation (111 Project)
- Hunan Provincial Natural Science Foundation
- Hunan Provincial Health Commission
- Hunan Provincial Department of Finance
- Free Exploration Program of Central South University
- Shenzhen Science and Technology Innovation Commission Foundation
Cite
APA
Wang, Z., Chen, B., Yang, D., Xu, W., Li, J., Chen, C., Wu, A., Xu, P., Fang, L., Chen, Y., & Li, Z. (2026). LINC00520 Regulates VDAC1 Oligomerization to Promote Cisplatin Resistance in Lung Adenocarcinoma. Frontiers in Bioscience-Landmark, 31(10). https://doi.org/10.31083/fbl53197
Vancouver
Wang Z, Chen B, Yang D, Xu W, Li J, Chen C, et al. LINC00520 Regulates VDAC1 Oligomerization to Promote Cisplatin Resistance in Lung Adenocarcinoma. Frontiers in Bioscience-Landmark. 2026;31(10). doi:10.31083/fbl53197
BibTeX
@article{Wang2026,
author = {Wang, Ziyao and Chen, Bisong and Yang, Desong and Xu, Wei and Li, Jingwei and Chen, Chuyang and Wu, Anbang and Xu, Ping and Fang, Li and Chen, Yuejun and Li, Zheng},
title = {LINC00520 Regulates VDAC1 Oligomerization to Promote Cisplatin Resistance in Lung Adenocarcinoma},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
volume = {31},
number = {10},
doi = {10.31083/fbl53197}
}
EUVIMED